UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 175 filers reported holding UNIQURE NV in Q1 2020. The put-call ratio across all filers is 0.53 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $9,573,000 | -74.2% | 284,160 | -72.4% | 0.14% | -70.0% |
| Q4 2020 | $37,174,000 | -10.6% | 1,028,898 | -8.9% | 0.45% | -41.0% |
| Q3 2020 | $41,575,000 | -26.0% | 1,128,827 | -9.5% | 0.76% | -26.4% |
| Q2 2020 | $56,196,000 | -57.3% | 1,247,135 | -55.0% | 1.04% | -71.9% |
| Q1 2020 | $131,604,000 | -28.1% | 2,773,525 | +8.6% | 3.69% | -15.7% |
| Q4 2019 | $182,971,000 | +92.9% | 2,553,325 | +5.9% | 4.38% | +37.8% |
| Q3 2019 | $94,863,000 | -27.3% | 2,410,125 | +44.4% | 3.18% | -14.0% |
| Q2 2019 | $130,473,000 | +67.3% | 1,669,525 | +27.7% | 3.69% | +61.8% |
| Q1 2019 | $77,994,000 | +107.6% | 1,307,522 | +0.3% | 2.28% | +51.0% |
| Q4 2018 | $37,565,000 | -37.1% | 1,303,422 | -20.5% | 1.51% | -17.7% |
| Q3 2018 | $59,676,000 | -2.8% | 1,639,900 | +1.0% | 1.84% | -12.0% |
| Q2 2018 | $61,402,000 | – | 1,624,400 | – | 2.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |